Literature DB >> 22207003

Apoptosis markers soluble Fas (sFas), Fas Ligand (FasL) and sFas/FasL ratio in patients with bacteremia: a prospective cohort study.

Reetta Huttunen1, Jaana Syrjänen, Risto Vuento, Janne Laine, Mikko Hurme, Janne Aittoniemi.   

Abstract

BACKGROUND: Recent studies have shown that immunoparalysis and lymphocyte apoptosis play a critical role in severe bacteremia. Monitoring apoptosis on a routine basis in septic patients has proved challenging. We here studied the prognostic value of apoptosis markers human soluble Fas (sFas), Fas ligand (FasL) and sFas/FasL ratio in patients with bacteremia.
METHODS: sFas (ng/ml) and FasL (ng/ml) concentrations in plasma were determined using commercial quantitative enzyme immunoassays (Quantikine®, R&D Systems Inc., Minneapolis, MN, USA) in 132 patients with bacteremia caused by Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic streptococcae or Escherichia coli.
RESULTS: Maximum sFas, minimum FasL and high sFas/FasL ratio predicted high SOFA score in bacteremic patients (p < 0.001, p = 0.003 and p < 0.001, respectively). AUC(ROC)'s in the prediction of high SOFA score for sFas, FasL and sFas/FasL ratio were 0.70 (CI 0.61-0.79), 0.65 (CI 0.56-0.75) and 0.72 (CI 0.63-0.80), respectively. High sFas concentrations and sFas/aFasL ratio, assessed using ROC curve as regards high SOFA (≥4) score, were associated with hypotension (p = 0.001 and p = 0.039, respectively). All of these markers predicted a high SOFA score independently in a logistic regression model. Maximum sFas, sFas/FasL ratio or minimum FasL during days 1-4 after blood culture were not associated with increased case fatality.
CONCLUSIONS: Apoptosis markers sFas, FasL or sFas/FasL ratio are associated with high SOFA score in bacteremia.
Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22207003     DOI: 10.1016/j.jinf.2011.12.006

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  6 in total

1.  Host derived biomarkers of inflammation, apoptosis, and endothelial activation are associated with clinical outcomes in patients with bacteremia and sepsis regardless of microbial etiology.

Authors:  William O Hahn; Carmen Mikacenic; Brenda L Price; Susanna Harju-Baker; Ronit Katz; Jonathan Himmelfarb; Mark M Wurfel; W Conrad Liles
Journal:  Virulence       Date:  2016-01-28       Impact factor: 5.882

2.  Increased apoptosis of peripheral blood neutrophils is associated with reduced incidence of infection in trauma patients with hemorrhagic shock.

Authors:  C Anne Morrison; Ana Moran; Shruti Patel; Maria del Pilar Huby Vidaurre; Matthew M Carrick; David J Tweardy
Journal:  J Infect       Date:  2012-10-09       Impact factor: 6.072

Review 3.  IMMUNE CELL PHENOTYPE AND FUNCTION IN SEPSIS.

Authors:  Thomas Rimmelé; Didier Payen; Vincenzo Cantaluppi; John Marshall; Hernando Gomez; Alonso Gomez; Patrick Murray; John A Kellum
Journal:  Shock       Date:  2016-03       Impact factor: 3.454

4.  The protective role of miR-223 in sepsis-induced mortality.

Authors:  Dan Liu; Zhiding Wang; Huijuan Wang; Feifei Ren; Yanqin Li; Sifan Zou; Jianqiao Xu; Lixin Xie
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

5.  Predictive Value of C-Reactive Protein (CRP) in Identifying Fatal Outcome and Deep Infections in Staphylococcus aureus Bacteremia.

Authors:  Tomi Mölkänen; Eeva Ruotsalainen; Esa M Rintala; Asko Järvinen
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

6.  Evaluating the discriminating capacity of cell death (apoptotic) biomarkers in sepsis.

Authors:  Christopher Duplessis; Michael Gregory; Kenneth Frey; Matthew Bell; Luu Truong; Kevin Schully; James Lawler; Raymond J Langley; Stephen F Kingsmore; Christopher W Woods; Emanuel P Rivers; Anja K Jaehne; Eugenia B Quackenbush; Vance G Fowler; Ephraim L Tsalik; Danielle Clark
Journal:  J Intensive Care       Date:  2018-11-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.